At thresholds above 50%, an even greater benefit can be seen; a retrospective study in patients with non-small-cell lung cancer found that PD-L1 expression levels of 90–100% were associated with an almost doubled overall response rate (60.0% versus 32.7%) and significantly prolonged progression-free survival (14.5 versus 4.1 months) compared to levels of 50–89% in a cohort of 187 patients receiving pembrolizumab [21]. Here, CD274 is linked to non-small cell lung carcinoma.